+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biologics Contract Manufacturing Market - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

  • ID: 5510892
  • Report
  • October 2021
  • Region: Asia Pacific
  • 139 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • Lonza Group
  • Recipharm Pharmaceuticals
The latest study analyzes the historical and present scenario of the biologics contract manufacturing market in Asia Pacific to gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the biologics contract manufacturing market in Asia Pacific in order to identify opportunities for stakeholders. The report also provides insightful information about the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period from 2021 to 2031.



The report offers intricate dynamics about different aspects of the biologics contract manufacturing market in Asia Pacific, which aids companies operating in the market in making strategic decisions. This study also elaborates on the significant changes that are anticipated to boost the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period. It also includes key indicator assessment that highlights growth prospects of the biologics contract manufacturing market in Asia Pacific and provides statistics related to the market in terms of value (US$ Mn).

This study covers detailed segmentation of the biologics contract manufacturing market in Asia Pacific, along with key information and competition outlook. The report provides company profiles of players that dominate the biologics contract manufacturing market in Asia Pacific, wherein various developments, expansions, and winning strategies adopted by these players have been presented in detail.

Key Questions Answered in this Report on Asia Pacific Biologics Contract Manufacturing Market


The report provides detailed information about the biologics contract manufacturing market in Asia Pacific based on comprehensive research on various factors that play a key role in accelerating the growth of the market. Information mentioned in the report answers path-breaking questions for companies that currently operate in the biologics contract manufacturing market in Asia Pacific and are looking for innovative methods to create a unique benchmark in the market in order to help them design successful strategies and make target-driven decisions.
  • Which segment of the biologics contract manufacturing market in Asia Pacific would emerge as a major revenue generator during the forecast period?
  • How are key market players successfully earning revenue in the biologics contract manufacturing market in Asia Pacific?
  • What would be the Y-o-Y growth trend of the biologics contract manufacturing market in Asia Pacific between 2021 and 2031?
  • What are the winning imperatives of leading players operating in the biologics contract manufacturing market in Asia Pacific?

Research Methodology - Asia Pacific Biologics Contract Manufacturing Market


The research methodology adopted by analysts for compiling the report on the biologics contract manufacturing market in Asia Pacific is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information obtained and endorsed by market-admissible sources, analysts have offered riveting observations and authentic forecasts of the biologics contract manufacturing market in Asia Pacific.

Primary research involved interviews with market stakeholders, investors, brand managers, vice presidents, and sales & marketing managers. Based on data obtained through interviews of genuine sources, analysts have emphasized the changing scenario of the biologics contract manufacturing market in Asia Pacific.

Secondary research involved study of annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the biologics contract manufacturing market in Asia Pacific.
Frequently Asked Questions about the Biologics Contract Manufacturing Market

What is the estimated value of the Biologics Contract Manufacturing Market?

The Biologics Contract Manufacturing Market was estimated to be valued at $2.7 Billion in 2021.

What is the growth rate of the Biologics Contract Manufacturing Market?

The growth rate of the Biologics Contract Manufacturing Market is 13.8%, with an estimated value of $9.8 Billion by 2031.

What is the forecasted size of the Biologics Contract Manufacturing Market?

The Biologics Contract Manufacturing Market is estimated to be worth $9.8 Billion by 2031.

Who are the key companies in the Biologics Contract Manufacturing Market?

Key companies in the Biologics Contract Manufacturing Market include Lonza Group, Samsung Biologics Co., Ltd., Patheon by Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Fujifilm Holding Corporation, AbbVie, Inc., Boehringer Ingelheim and WuXi Biologics.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • Lonza Group
  • Recipharm Pharmaceuticals

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology3. Executive Summary: Global & Asia Pacific Biologics Contract Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Biologics Contract Manufacturing: Overview
5.2. Trends in Biopharma Contract Manufacturing
5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.4. COVID-19 Pandemic Impact on Industry
6. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Molecular Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Country/Sub-Region
7.1. Key Findings
7.2. Market Value Forecast, by Country/Sub-Region
7.2.1. Japan
7.2.2. South Korea
7.2.3. Taiwan
7.2.4. Singapore
7.2.5. Thailand
7.2.6. India
7.2.7. Rest of Asia Pacific
7.3. Market Attractiveness Analysis, by Country/Sub-Region
8. Japan Biologics Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Type, 2017-2031
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.2.4. Molecular Therapy
8.2.5. Others
8.3. Market Attractiveness Analysis
8.3.1. By Type
9. South Korea Biologics Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017-2031
9.2.1. Monoclonal Antibodies
9.2.2. Recombinant Proteins
9.2.3. Vaccines
9.2.4. Molecular Therapy
9.2.5. Others
9.3. Market Attractiveness Analysis
9.3.1. By Type
10. Taiwan Biologics Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017-2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Molecular Therapy
10.2.5. Others
10.3. Market Attractiveness Analysis
10.3.1. By Type
11. Singapore Biologics Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Molecular Therapy
11.2.5. Others
11.3. Market Attractiveness Analysis
11.3.1. By Type
12. Thailand Biologics Contract Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Molecular Therapy
12.2.5. Others
12.3. Market Attractiveness Analysis
12.3.1. By Type
13. India Biologics Contract Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Monoclonal Antibodies
13.2.2. Recombinant Proteins
13.2.3. Vaccines
13.2.4. Molecular Therapy
13.2.5. Others
13.3. Market Attractiveness Analysis
13.3.1. By Type
14. Rest of Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Monoclonal Antibodies
14.2.2. Recombinant Proteins
14.2.3. Vaccines
14.2.4. Molecular Therapy
14.2.5. Others
14.3. Market Attractiveness Analysis
14.3.1. By Type
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Lonza Group
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Samsung Biologics Co., Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Patheon by Thermo Fisher Scientific, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Siegfried Holding AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Strategic Overview
15.3.4.4. SWOT Analysis
15.3.5. Cambrex Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Strategic Overview
15.3.6.4. SWOT Analysis
15.3.7. Recipharm Pharmaceuticals
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Catalent Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Strategic Overview
15.3.8.4. SWOT Analysis
15.3.9. WuXi Biologics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. Fujifilm Holding Corporation
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Strategic Overview
15.3.10.4. SWOT Analysis
15.3.11. AbbVie, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Strategic Overview
15.3.11.4. SWOT Analysis
List of Tables
Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2031
Table 02: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
Table 03: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 04: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 05: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 06: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 07: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 08: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 09: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017-2031
List of Figures
Figure 01: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Type, 2020
Figure 03: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Country/Sub-Regions, 2020
Figure 04: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031
Figure 05: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 06: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017?2031
Figure 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017?2031
Figure 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017?2031
Figure 09: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017?2031
Figure 10: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017-2031
Figure 11: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021-2031
Figure 12: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031
Figure 13: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 14: Japan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 15: Japan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 16: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 17: South Korea Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 18: South Korea Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 19: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 20: Taiwan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 21: Taiwan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 22: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 23: Singapore Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 24: Singapore Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 25: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 26: Thailand Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 27: Thailand Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 28: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 29: India Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 30: India Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Figure 31: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 32: Rest of Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031
Figure 33: Rest of Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021-2031
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Lonza Group
  • Samsung Biologics Co., Ltd.
  • Patheon by Thermo Fisher Scientific, Inc.
  • Cambrex Corporation
  • Siegfried Holding AG
  • Fujifilm Holding Corporation
  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Recipharm Pharmaceuticals
  • WuXi Biologics
  • Catalent, Inc.
Note: Product cover images may vary from those shown